

GSK481

Cat. No.: HY-100131 CAS No.: 1622849-58-4 Molecular Formula: $C_{21}H_{19}N_3O_4$ Molecular Weight: 377.39 RIP kinase Target: Pathway: **Apoptosis**

Storage: Powder -20°C

2 years

3 years

-80°C 6 months In solvent

> -20°C 1 month

0- N-	NH	N-O	
/	U		

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: ≥ 35 mg/mL (92.74 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.6498 mL	13.2489 mL	26.4978 mL
	5 mM	0.5300 mL	2.6498 mL	5.2996 mL
	10 mM	0.2650 mL	1.3249 mL	2.6498 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (6.62 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	GSK481 is a highly potent, selective, and specific receptor interacting protein 1 (RIP1) kinase inhibitor with an IC $_{50}$ of 1.3 nM, which inhibits Ser 166 phosphorylation in wild-type human RIP1 (IC $_{50}$ =2.8 nM). GSK481 also exhibits excellent translation in the U937 cellular assay with an IC $_{50}$ of 10 nM $^{[1]}$.

IC50: 1.3 nM (RIP1), 2.8 nM (Ser 166 phosphorylation in wild-type human RIP1) $^{[1]}$ IC₅₀ & Target

In Vitro	GSK481 (300 nM; 2 hours; Jurkat cells) abrogates the RIP3 up-regulation induces by both TNFa and shikonin in live and dead cells, indicating that necroptosis is in fact induced by both agents ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis Analysis ^[2]		
	Cell Line:	Jurkat cells	
	Concentration:	300 nM	
	Incubation Time:	2 hours	
	Result:	Increased levels of detectable apoptosis induced by TNFa and shikonin.	
In Vivo	GSK481 inhibits Ser^{166} phosphorylation in three mouse RIP1 mutants (IC ₅₀ =18~110 nM) more potently than in wild-type mouse ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Harris PA et al. DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors. J Med Chem, 2016 Mar 10, 59(5):2163-78.

[2]. Lee HL, et al. Simultaneous flow cytometric immunophenotyping of necroptosis, apoptosis and RIP1-dependent apoptosis. Methods. 2018 Feb 1;134-135:56-66.

Caution: Product has not been fully validated for medical applications. For research use only.